Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Mylan Receives FDA Approval For Generic Version Of Thyroid Deficiency Treatment Cytomel(R)
Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).
generic viagra online
Sciele Pharma Announces Availability Of Ulesfia (Benzyl Alcohol Lotion 5%), First Prescription Non-Neurotoxic Head Lice Treatment
Sciele Pharma, Inc., a Shionogi Company, announced the availability of Ulesfia (Benzyl Alcohol Lotion 5%), the first and only prescription medication that kills head lice by asphyxiation without potential neurotoxic side effects. Approved by the U.S. Food & Drug Administration (FDA), Ulesfia is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Ulesfia is available now by prescription nationwide in time for peak head lice season.
plastic surgery before after
News of the day
Arizona, North Carolina Legislatures Take Action On Abortion, Sex Education Measures
The following summarizes news coverage on women"s health-related legislation in Arizona and North Carolina. ~ Arizona: The Arizona Senate Public Safety and Human Services Committee on Wednesday voted 4-3 to approve a bill (S.B. 1206) that would place several restrictions on abortion rights and allow pharmacists or other health care providers to refuse to distribute emergency contraception based on religious or moral objections, the AP/Arizona Daily Star reports. The state House passed an identical bill in March. The measure would impose a 24-hour waiting period for women seeking abortion procedures and mandate that doctors inform women about risks and alternatives. It also would toughen an exisiting parental consent requirement for minors seeking abortion. The bill requires an in-person consultation before the 24-hour waiting period, which would increase costs for women who are forced to travel to a clinic twice, according to Planned Parenthood of Arizona President Bryan Howard. The Legislature approved bills with similar restrictions in recent years, but the measures were vetoed by then-Gov. Janet Napolitano (D). Current Gov. Jan Brewer (R) has said she supports mandatory disclosures and a 24-hour waiting period (Billeaud, AP/Arizona Daily Star, 6/10).~ North Carolina: The North Carolina Senate Mental Health and Youth Services Committee this week approved a bill (S. 221) that would require all public school systems to offer information on the use of contraceptives to students in grades seven through nine, the AP/Raleigh News & Observer reports. The information would be presented as part of a larger reproductive health education program that would maintain the abstinence-only education curricula currently taught at nearly all of the state"s 115 school districts. Parents would be permitted to prevent children from participating in the classes with contraceptive information. The measure is a revised version of state House-approved legislation (H.B. 88) that would have required schools to teach two separate abstinence-only and comprehensive sex education tracks. If the full state Senate passes the new bill, the two chambers will meet to negotiate a compromise (Robertson, AP/Raleigh News & Observer, 6/11).
Sexual Health

MAP Pharmaceuticals Phase 3 Trial Of Levadex™ Migraine Product Candidate Meets All Four Primary Endpoints

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX™ orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing. Patients taking LEVADEX therapy (formerly referred to as MAP0004) had statistically significant improvement at two hours compared to patients on placebo for each of the primary endpoints: - Pain relief: 58.7 percent of patients who received LEVADEX compared with 34.5 percent for placebo (pFREEDOM-301 Trial Design FREEDOM-301 is a multi-center, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the safety and efficacy of LEVADEX as a potential treatment for acute migraine. Primary efficacy measures include pain relief, and being phonophobia, photophobia and nausea free at two hours after dosing. FREEDOM-301, the first Phase 3 study of LEVADEX therapy, was conducted pursuant to a Special Protocol Assessment with the U.S. Food and Drug Administration. A total of 792 patients (ages 18 to 65) were included in the modified intent to treat population used for primary data analysis, as specified in the protocol. Patients enrolled in the trial were evaluated for the treatment of a single moderate or severe migraine, and then were given the option to continue in an open label, long-term safety arm. This safety arm is targeting 300 patients for six months and 150 patients for 12 months, and over 500 patients are continuing in this arm of the trial. About LEVADEX™ LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company"s proprietary TEMPO® inhaler. LEVADEX has been designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action and sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy. LEVADEX is designed to incorporate the multiple beneficial mechanisms of action that allow DHE to block initiation of migraine, limit pain, reduce inflammation and stop a migraine at any point in the migraine cycle. Based on research to date, including the FREEDOM-301 trial, the company believes the unique pharmacokinetic profile of LEVADEX has the potential to effectively treat migraines, while minimizing the side effects commonly seen with DHE and other currently available medicines. About Migraine Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies. Migraine patients report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles. The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually. MAP Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009